Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study

In the article “Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study” by P. O’Connor et al.,¹ there are errors in table 3 and figure 2. In the corrected portion of table 3, the layout of the data for “Patients with ≥1 relapse” in the teriflunomide 14 mg/14 mg and 7 mg/7 mg columns has been correctly adjusted and shifted down one row. The left panel of figure 2A shows both unconfirmed and confirmed relapses, while the right panel shows confirmed relapses only. In the left panel of figure 2B, the mean (±SD) values should read as follows: 14 mg/14 mg, 0.12 (0.06); 7 mg/7 mg, 0.21 (0.06); placebo/14 mg, 0.24 (0.09); placebo/7 mg, 0 (0.08). In addition, the numbers of patients were transposed between the 7 mg/7 mg group (should be 252 rather than 106 as originally published) and the placebo/14 mg group (should be 106 rather than 252 as originally published). These corrected values required an adjustment to the y axis (−0.2 to 0.5). These errors do not change the conclusions of the article. See the corrected portion of table 3 and figure 2B below. The authors regret the errors.

• Download figure
• Open in new tab
• Download powerpoint

Figure 2

• © 2016 American Academy of Neurology